摘要
目的探讨吉非替尼单药治疗化疗失败的晚期非小细胞肺癌的疗效及不良反应。方法对45例IIIB~IV期经化疗失败的晚期非小细胞肺癌用吉非替尼每次250 mg/d口服。第一次用药后4周评价疗效,以后每8周1次或出现新的症状及原有症状加重时随时评价。结果45例均可评价疗效,完全缓解(CR)1例,部分缓解(PR)15例,客观缓解率(CR+PR)为35.6%;疾病控制率(CR+PR+SD)为68.9%。不良反应:30例有皮肤改变表现(脱屑、座疮),15例有轻度腹泻。结论吉非替尼对化疗失败晚期非小细胞肺癌具有一定疗效,不良反映轻微。
Objective To evaluate the efficacy and adverse effects of single - drug Iressa in treatment of non - small - cell lung cancer (NSCLC) patients who failed in previous chemotherapy. Methods Forty - five patients with stage ⅢB~Ⅳ NSCLC who had failed chemotherapy received 250 mg oral dises of gefitinib. Four weeks after the start of gefitinib the effect was assessed, then once every 8 weeks or if the symptom progressed,the evaluation was repeated. Results All 45 patients were evaluable, overall response rate was 40% , and disease control rate (DCR) was 73.3% which included 2 complete response ( CR ), 16partial response ( PR ), 15 stable disease. The most common Adverse effects were rash and diarrhea with 66.7% and 33.3% ,respectively. Conclusions Gefitinib is effective and tolemble in the treatment of patients with advanced NSCLC failed to prior chemotherapy.
出处
《医学信息(内.外科版)》
2009年第8期680-681,684,共3页
Medical Information Operations Sciences Fascicule
关键词
非小细胞肺癌
吉非替尼
non - small cell lung cancer (NSCLC)
gefitinib.